These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 20658186)

  • 1. Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.
    Ho D; Yan L; Iwatsubo K; Vatner DE; Vatner SF
    Heart Fail Rev; 2010 Sep; 15(5):495-512. PubMed ID: 20658186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart.
    Vatner DE; Asai K; Iwase M; Ishikawa Y; Shannon RP; Homcy CJ; Vatner SF
    Am J Cardiol; 1999 Jun; 83(12A):80H-85H. PubMed ID: 10750593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac adenylyl cyclase overexpression precipitates and aggravates age-related myocardial dysfunction.
    Mougenot N; Mika D; Czibik G; Marcos E; Abid S; Houssaini A; Vallin B; Guellich A; Mehel H; Sawaki D; Vandecasteele G; Fischmeister R; Hajjar RJ; Dubois-Randé JL; Limon I; Adnot S; Derumeaux G; Lipskaia L
    Cardiovasc Res; 2019 Oct; 115(12):1778-1790. PubMed ID: 30605506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene.
    Okumura S; Suzuki S; Ishikawa Y
    J Pharmacol Sci; 2009 Mar; 109(3):354-9. PubMed ID: 19270422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.
    Zhao Z; Babu GJ; Wen H; Fefelova N; Gordan R; Sui X; Yan L; Vatner DE; Vatner SF; Xie LH
    Am J Physiol Heart Circ Physiol; 2015 Feb; 308(3):H240-9. PubMed ID: 25485900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.
    Gao MH; Tang T; Guo T; Miyanohara A; Yajima T; Pestonjamasp K; Feramisco JR; Hammond HK
    J Biol Chem; 2008 Nov; 283(48):33527-35. PubMed ID: 18838385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts.
    Liu X; Thangavel M; Sun SQ; Kaminsky J; Mahautmr P; Stitham J; Hwa J; Ostrom RS
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):359-69. PubMed ID: 17934720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA/STAT3-dependent pathway.
    Wu YS; Chen CC; Chien CL; Lai HL; Jiang ST; Chen YC; Lai LP; Hsiao WF; Chen WP; Chern Y
    J Biomed Sci; 2017 Sep; 24(1):68. PubMed ID: 28870220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac-directed expression of a catalytically inactive adenylyl cyclase 6 protects the heart from sustained β-adrenergic stimulation.
    Gao MH; Lai NC; Giamouridis D; Kim YC; Guo T; Hammond HK
    PLoS One; 2017; 12(8):e0181282. PubMed ID: 28767701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling.
    Tepe NM; Lorenz JN; Yatani A; Dash R; Kranias EG; Dorn GW; Liggett SB
    Biochemistry; 1999 Dec; 38(50):16706-13. PubMed ID: 10600134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of type 5 adenylyl cyclase prevents β-adrenergic receptor cardiomyopathy: a novel approach to β-adrenergic receptor blockade.
    Yan L; Vatner SF; Vatner DE
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1521-8. PubMed ID: 25193472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase.
    Vatner DE; Asai K; Iwase M; Ishikawa Y; Wagner TE; Shannon RP; Homcy CJ; Vatner SF
    J Clin Invest; 1998 May; 101(9):1916-22. PubMed ID: 9576756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice.
    Lai NC; Tang T; Gao MH; Saito M; Takahashi T; Roth DM; Hammond HK
    J Am Coll Cardiol; 2008 Apr; 51(15):1490-7. PubMed ID: 18402905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression and β-adrenergic signaling are altered in hypoplastic left heart syndrome.
    Miyamoto SD; Stauffer BL; Polk J; Medway A; Friedrich M; Haubold K; Peterson V; Nunley K; Nelson P; Sobus R; Stenmark KR; Sucharov CC
    J Heart Lung Transplant; 2014 Aug; 33(8):785-93. PubMed ID: 24793904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization.
    Sulakhe PV; Vo XT
    Mol Cell Biochem; 1995; 149-150():103-26. PubMed ID: 8569720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic AMP-dependent inotropic effects are differentially regulated by muscarinic G(i)-dependent constitutive inhibition of adenylyl cyclase in failing rat ventricle.
    Hussain RI; Afzal F; Mørk HK; Aronsen JM; Sjaastad I; Osnes JB; Skomedal T; Levy FO; Krobert KA
    Br J Pharmacol; 2011 Feb; 162(4):908-16. PubMed ID: 21039419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress.
    Vatner SF; Yan L; Ishikawa Y; Vatner DE; Sadoshima J
    Circ J; 2009 Feb; 73(2):195-200. PubMed ID: 19106458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration.
    Iwatsubo K; Minamisawa S; Tsunematsu T; Nakagome M; Toya Y; Tomlinson JE; Umemura S; Scarborough RM; Levy DE; Ishikawa Y
    J Biol Chem; 2004 Sep; 279(39):40938-45. PubMed ID: 15262973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function.
    Akhter SA; Eckhart AD; Rockman HA; Shotwell K; Lefkowitz RJ; Koch WJ
    Circulation; 1999 Aug; 100(6):648-53. PubMed ID: 10441103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes.
    Ostrom RS; Bundey RA; Insel PA
    J Biol Chem; 2004 May; 279(19):19846-53. PubMed ID: 15007069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.